Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.64 USD
-0.03 (-1.12%)
Updated Sep 25, 2024 10:30 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ALLO 2.64 -0.03(-1.12%)
Will ALLO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALLO
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Other News for ALLO
Biotech Alert: Searches spiking for these stocks today
Cellectis: Cheap With Promising But Speculative Cancer Therapies
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Buy Rating Affirmed for Allogene Therapeutics on Strong Financials and Positive Pipeline Prospects
Optimistic Outlook for Allogene Therapeutics with a Strong Buy Rating